13
Click icon to What’s in a name – biosimilars? Kevin Grant Section Head, Office of Laboratories & Scientific Services, Monitoring & Compliance Group, TGA ARCS Scientific Congress 2014 10 September 2014

What’s in a name - biosimilars?

Embed Size (px)

DESCRIPTION

The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the definition of the term 'biosomilars' and its features

Citation preview

Page 1: What’s in a name - biosimilars?

Click icon to add picture

What’s in a name – biosimilars?

Kevin Grant

Section Head, Office of Laboratories & Scientific Services,Monitoring & Compliance Group, TGA

ARCS Scientific Congress 2014

10 September 2014

Page 2: What’s in a name - biosimilars?

2

What is a biosimilar?A biosimilar is a “copy” version of an approved biological medicine with demonstrated similarity in physicochemical, biological and immunological characteristics, efficacy and safety, based on a comprehensive comparability study.

Biosimilars are variously termed:

• Similar Biotherapeutic Products (WHO)

• Similar Biological Medicinal Products (EU/TGA)

• “biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product” (US FDA)

• follow-on biologics (PMDA, Japan) and

• subsequent entry biologics (Health Canada).

What’s in a name – biosimilars?

Page 3: What’s in a name - biosimilars?

3

Biosimilar ≠ generic

What’s in a name – biosimilars?

Page 4: What’s in a name - biosimilars?

4

1.Size

What’s in a name – biosimilars?

Asprin vs IgGFrom: Kozlowski et al NEJM 2011;365:385-388

Page 5: What’s in a name - biosimilars?

5

1. Size

2. Complexity – 4 levels of structure

Biosimilar

What’s in a name – biosimilars?

Page 6: What’s in a name - biosimilars?

6

1. Size

2. Complexity - glycosylation

What’s in a name – biosimilars?

Page 7: What’s in a name - biosimilars?

7

Variability – e.g. EPO • Mass = 27948±285 deglycosylated 18240±4

• 2 disulphide bonds• 3 N-glycosylation • 2 O-glycosylation sites• Many types of glycans• C-terminal truncation

Even the most controlled biotechnological process produces a spectrum of 100 000s of molecules – all having different activity, half-life and potential to induce an immune reaction.

What’s in a name – biosimilars?

Page 8: What’s in a name - biosimilars?

8

1. Size

2. Complexity

3. Variability

Biosimilar ≠ generic

Comparable ≠ bioequivalent

What’s in a name – biosimilars?

Page 9: What’s in a name - biosimilars?

9

Naming safety • Information• Warning• Clarity

What’s in a name – biosimilars?

Page 10: What’s in a name - biosimilars?

10

Naming safety For biosimilars:• Identify reference product• Distinguish from other biosimilars• Clarify use

What’s in a name – biosimilars?

Page 11: What’s in a name - biosimilars?

11

Naming safety TGA biosimilar naming policy:• ABN of reference product• Biosimilar identifier based on INN• Linked to advice in PI

What’s in a name – biosimilars?

Page 12: What’s in a name - biosimilars?

12

Thank you!

What’s in a name – biosimilars?

Page 13: What’s in a name - biosimilars?